Study of Angiotensin Receptor Blockers to Slow Progression of Mild to Moderate Aortic Stenosis and Improve Heart Function

What this Trial Is About

Researchers are investigating the effects of angiotensin receptor blockers ARBs on people with mild-to-moderate aortic stenosis, a condition where the hearts aortic valve narrows and affects blood flow. The study explores whether ARBs can slow the progression of this valve narrowing and reduce changes in the heart muscle. This is a randomized controlled trial aiming to test the impact of ARBs on valve stenosis and heart remodeling in affected patients. Participants will be randomly assigned to receive either an angiotensin receptor blocker or a placebo, both taken orally once daily for two years. The study compares the changes in aortic stenosis progression and heart structure between these two groups over this period. The trial uses a quadruple masking design to ensure unbiased results. During the study, participants will undergo evaluations at the start and after two years, measuring changes in the anatomy of aortic stenosis, peak aortic jet velocity, aortic valve area, left ventricular size, mass, and fibrosis. Researchers will monitor these heart function markers to assess the treatment effect. The total participation time spans two years with regular assessments to track safety and heart health changes.

Angiotensin Receptor Blockers in Aortic Stenosis